Showing results (1451-1460 of 1,648) with videos related to
Sort By:
Pageof 165
Oncogenesis|May 10, 2016
Association of p53 codon72 Arg>Pro polymorphism with susceptibility to nasopharyngeal carcinoma: evidence from a case-control study and meta-analysisS K Sahu, S Chakrabarti, S D Roy, et al.Nature Communications|February 8, 2024
Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitorSvenja M Sake, Xiaoyu Zhang, Manoj Kumar Rajak, et al.Biorxiv : the Preprint Server for Biology|April 12, 2022
Targeted protein S-nitrosylation of ACE2 as potential treatment to prevent spread of SARS-CoV-2 infectionChang-Ki Oh, Tomohiro Nakamura, Nathan Beutler, et al.ACS Medicinal Chemistry Letters|August 23, 2014
Lead optimization of imidazopyrazines: a new class of antimalarial with activity on Plasmodium liver stagesBin Zou, Advait Nagle, Arnab K Chatterjee, et al.The Plant Cell|October 12, 2022
Climate change challenges, plant science solutionsNancy A Eckardt, Elizabeth A Ainsworth, Rajeev N Bahuguna, et al.Biorxiv : the Preprint Server for Biology|June 9, 2020
A Large-scale Drug Repositioning Survey for SARS-CoV-2 AntiviralsLaura Riva, Shuofeng Yuan, Xin Yin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2020
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast CancerPreeti Narayan, Tatiana M Prowell, Jennifer J Gao, et al.Journal of Medicinal Chemistry|February 9, 2024
Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel WarheadN G R Dayan Elshan, Karen C Wolff, Laura Riva, et al.Journal of Medicinal Chemistry|June 8, 2011
Imidazolopiperazines: hit to lead optimization of new antimalarial agentsTao Wu, Advait Nagle, Kelli Kuhen, et al.Nature Communications|June 4, 2021
Drug repurposing screens identify chemical entities for the development of COVID-19 interventionsMalina A Bakowski, Nathan Beutler, Karen C Wolff, et al.Pageof 165